Deals & IPOs

Pivotal Group buys Phoenix animal health maker Precision Science

Pivotal Group buys Precision Science, a Phoenix animal health contract manufacturer founded in 1989, and funds a 130,000-square-foot North Phoenix plant two-thirds complete at announcement.

By Olivia Hart

4 min read

Pivotal Group Acquires Precision Science To Build Animal Health Platform
Pivotal Group Acquires Precision Science To Build Animal Health Platformstevepb / pixabay

What's News

  • Pivotal Group acquired Precision Science, a Phoenix contract manufacturer of animal health pharmaceuticals, medicated feed additives and supplements founded in 1989
  • The 130,000-square-foot North Phoenix facility was roughly two-thirds complete at announcement and adds three manufacturing lines plus liquid-product capacity
  • Financial terms, revenue and valuation were not disclosed; it is Pivotal's first animal health acquisition
  • Bryan Vincent continues as CEO of Precision Science; Francis Najafi is founder and CEO of Pivotal Group
  • Pivotal's prior holdings include Network Solutions, Global Capacity, Global Meet, MegaPath and Promontory in Park City, Utah

Pivotal Group has acquired Precision Science, a Phoenix contract manufacturer of animal health pharmaceuticals, medicated feed additives and supplements, and is putting capital into a 130,000-square-foot plant in North Phoenix that stood about two-thirds complete at announcement. It is the Phoenix investment firm's first deal in animal health.

No price was disclosed. Neither side released purchase terms, revenue, valuation or a market-size estimate for animal health.

Scale check: 130,000 square feet is roughly two NFL playing fields, or about 12,000 square meters.

What does the new plant actually add?

Three manufacturing lines, entry into liquid products, and more analytical, product-development, storage and logistics capacity. Pivotal has invested additional capital and operating resources since closing the transaction.

Precision Science was founded in 1989 and performs contract manufacturing plus product research and development for global animal health companies, supplement brands and entrepreneurs. Automation is the stated mechanism for scaling. Pivotal says the buildout should lift production efficiency and open capacity for customers developing or expanding animal health products. The company expects the facility and the wider investment program to create manufacturing and management jobs in Phoenix.

Takeaway: the deal buys a running 35-year-old manufacturer and funds the plant that scales it.

Why animal health companies hire someone else to make the product

Animal health companies routinely use contract manufacturers to develop and produce pharmaceuticals, supplements and feed additives rather than build a dedicated facility for every product. The contractor carries the equipment, technical expertise, quality controls and regulatory systems needed to work across multiple categories. For the customer, that arrangement can support product development, manufacturing scale and market expansion without tying up capital in plant.

Precision Science's infrastructure includes an FDA-registered facility, an internal laboratory and established quality systems. Management says the company will keep operating with an emphasis on quality, safety and regulatory compliance, and Pivotal intends to fund technology, employees, manufacturing equipment and product-development functions.

Takeaway: the value proposition here is regulatory and operational capability, not a proprietary drug.

What did Pivotal say, and what did it leave out?

Francis Najafi, founder and CEO of Pivotal Group, framed the purchase in market terms:

"The acquisition of Precision Science represents an exciting opportunity for Pivotal Group to build a leading platform focused on animal health starting with supplements and pharmaceuticals. We were particularly attracted to the growing animal health market, and Precision Science's commitment to quality and innovation. We look forward to supporting the new platform with the capital and resources needed to expand capabilities, invest in people and technology, and build on the strong foundation that Precision Science established over more than three decades."

Bryan Vincent, CEO of Precision Science, who stays on to lead the company, pointed to the workforce:

"Our people have built Precision Science by earning our clients' trust every day, and their expertise and dedication are what will carry us forward. Our clients are asking us to look ahead—to anticipate where animal health is going and invest in the capabilities that will help them get there. Pivotal's acquisition provides the resources to invest in people, advance product development and build manufacturing capabilities to meet client needs."

Both quotes lean on the same unquantified claim: a growing animal health market. Neither mentions price, revenue, customer concentration, capacity utilization or the specific segments — nutrition, pharmaceuticals, medicated feed additives — that carry the growth. Vincent's reference to client demand is the seller relaying a demand signal, not independent evidence of it.

Takeaway: the deal rationale rests on market growth that neither party has sized or substantiated with figures.

Who is Pivotal Group?

Pivotal Group is a Phoenix-based private equity investor and company builder founded by Francis Najafi. Previous investments include technology companies such as Network Solutions, Global Capacity, Global Meet and MegaPath. It also owns and operates Promontory, a luxury mountain community in Park City, Utah — an asset that gives the firm property exposure unrelated to animal health.

The firm's stated filter is businesses with established operations and long-term growth opportunities, which fits a 1989-founded company with an existing client base and an FDA-registered facility.

What to watch

The checkable milestones are construction: finishing the remaining third of the North Phoenix building, commissioning three lines, moving into liquid products, and hiring manufacturing and management staff in Phoenix.

The harder questions sit in the numbers nobody has published. With no purchase price, no revenue figure and no capacity data on the record, an outside observer cannot judge what Pivotal paid, what utilization the new plant must reach, or how much of the animal health growth narrative converts into volume.

The next real disclosures will come from the buildout itself — a completed plant, running lines and hired staff — or from a filing that finally puts financial terms on the record. Until then, the deal stands as a 35-year-old Phoenix manufacturer under new ownership, mid-construction, with its economics still private.

Source: pulse2.com

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Staff writer covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,312 articles

Related articles

« Previous article